Notice: This company has been marked as potentially delisted and may not be actively trading. Elicio Therapeutics (ELTX) Stock Forecast & Price Target Add Compare Share Share Analyst Forecasts Stock AnalysisAnalyst ForecastsCompetitorsEarningsHeadlinesInsider TradesOwnershipShort InterestTrends Get the Latest News and Ratings for ELTX and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Elicio Therapeutics and its competitors. Enter your email to sign up for newsletter Sign Up ELTX Analyst Ratings Over TimeTypeCurrent Forecast10/25/23 to 10/24/241 Month Ago9/25/23 to 9/24/243 Months Ago7/27/23 to 7/26/241 Year Ago10/25/22 to 10/25/23Strong Buy0 Strong Buy rating(s)0 Strong Buy rating(s)0 Strong Buy rating(s) N/A Buy1 Buy rating(s)1 Buy rating(s)1 Buy rating(s) N/A Hold1 Hold rating(s)1 Hold rating(s)1 Hold rating(s) N/A Sell0 Sell rating(s)0 Sell rating(s)0 Sell rating(s) N/A Consensus Price Target$10.00$10.00$10.00N/AForecasted Upside117.39% Upside100.80% Upside106.19% UpsideN/AConsensus RatingModerate BuyModerate BuyModerate BuyN/A Billionaires Spot Once-In-25-Year Wealth Opportunity (Ad)Why November 7th Will Impact Stocks More Than The Election Just 48 hours after the 2024 Presidential Election… A man from a completely different government branch is going to stand up, say a few words… and make history in the stock market. Click here for the full story. ELTX Analyst Recommendations By MonthAnalyst Ratings Chart DescriptionThe chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.Skip Chart & View Analyst Rating History ELTX Price Targets by MonthAverage Share Price and Price Target by Month Chart DescriptionThe chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table Elicio Therapeutics Stock vs. The CompetitionTypeElicio TherapeuticsMedical CompaniesS&P 500Consensus Rating Score 2.50 2.79 2.50Consensus RatingModerate BuyModerate BuyHoldPredicted Upside117.39% Upside9,785.20% Upside8.47% UpsideNews Sentiment RatingNeutral NewsSee Recent ELTX NewsNeutral NewsPositive News Recent Analyst Forecasts and Stock Ratings All Ratings Strong Buy Buy Hold Sell Rating Show All Upside > 100% Upside 50% - 100% Upside 20% - 50% Upside 10% - 20% Upside 0% - 10% Downside 0% - 10% Downside 10% - 20% Downside 20% - 50% Downside 50% - 100% Downside > 100% Upside/Downside All Actions Upgrades Downgrades Initiates Coverage Raises Target Lowers Target Reiterates Rating Action Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Years 5 Years Time Frame Start Date End Date Most Recent from Each Brokerage All Show Export to Excel DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails8/23/2024HC Wainwright2 of 5 stars Reiterated RatingBuy ➝ Buy$10.00 ➝ $10.00+119.78%4/1/2024Oppenheimer3 of 5 stars Reiterated RatingMarket Perform ➝ Market PerformAnalyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 07:14 AM ET. ELTX Forecast - Frequently Asked Questions What is Elicio Therapeutics' forecast for 2024? According to the research reports of 2 Wall Street equities research analysts, the average twelve-month stock price forecast for Elicio Therapeutics is $10.00, with a high forecast of $10.00 and a low forecast of $10.00. Should I buy or sell Elicio Therapeutics stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Elicio Therapeutics in the last twelve months. There is currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ELTX shares. Does Elicio Therapeutics's stock price have much upside? According to analysts, Elicio Therapeutics's stock has a predicted upside of 117.39% based on their 12-month stock forecasts. What analysts cover Elicio Therapeutics? Elicio Therapeutics has been rated by research analysts at HC Wainwright in the past 90 days. Do Wall Street analysts like Elicio Therapeutics more than its competitors? Analysts like Elicio Therapeutics less than other "medical" companies. The consensus rating score for Elicio Therapeutics is 2.50 while the average consensus rating score for "medical" companies is 2.79. Learn more on how ELTX compares to other companies. Stock Forecasts and Research Tools Related Companies Nkarta Stock Forecast Corbus Pharmaceuticals Stock Forecast Rezolute Stock Forecast Galecto Stock Forecast Organigram Stock Forecast DiaMedica Therapeutics Stock Forecast Atossa Therapeutics Stock Forecast Ventyx Biosciences Stock Forecast Greenwich LifeSciences Stock Forecast Forte Biosciences Stock Forecast Today's Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top Rated Stocks Top Rated Stocks Top Rated Dividend Stocks Top Rated Small-Cap Stocks Top Rated Tech Stocks Most Upgraded Stocks Most Downgraded Stocks Lowest Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Billionaires Spot Once-In-25-Year Wealth Opportunity (Ad)Why November 7th Will Impact Stocks More Than The Election Just 48 hours after the 2024 Presidential Election… A man from a completely different government branch is going to stand up, say a few words… and make history in the stock market. Click here for the full story. This page (NASDAQ:ELTX) was last updated on 10/24/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredMusk warns humanity: “Obsolete”The 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredWatch this before it gets removed If you missed it, my emergency election broadcast is now available - but will be removed soonPorter & Company | Sponsored #1 Pre-IPO Opportunity For 2024 [Take Action Now!]According to James, the largest IPO in history could kick off in a matter of weeks. I’m talking about Starl...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredGoldman Sachs’ AI warningAfter warning of last year's historic bank run, weeks in advance... Legendary stock-picker Marc Chaikin jus...Chaikin Analytics | SponsoredAmerica’s Election NightmareThanks to a new law signed by President Biden, a small group of powerful people could decide who is installed ...Banyan Hill Publishing | SponsoredIt’s delivered 859% in 2.5 months…We’ve gotten a lot of messages asking… what should we buy if Trump wins? What should we buy if Kamala wins?...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Elicio Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Elicio Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.